Enzymatically responsive nanocarriers targeting PD-1 and TGF-β pathways reverse immunotherapeutic resistance and elicit robust therapeutic efficacy

Enzymatically responsive nanocarriers targeting PD-1 and TGF-β pathways reverse immunotherapeutic resistance and elicit robust therapeutic efficacy

Abstract Immune checkpoint inhibitors (ICIs) have revolutionized lung cancer treatment, yet resistance remains a challenge. Co-inhibition of PD-1/PD-L1 and TGF-β shows promise but faces limited efficacy and systemic toxicity. We developed gelatinase-responsive nanoparticles (GPNPs) delivering anti-P...

Full description

Saved in:
Bibliographic Details
Main Authors: Ying-Tzu Yen, Zhifan Zhang, Anni Chen, Yuling Qiu, Qin Liu, Qin Wang, Chunhua Li, Chun Wang, Xiaoping Qian, Jie Shao, Fanyan Meng, Lixia Yu, Baorui Liu, Rutian Li
Format: Article
Language:English
Published: BMC 2025-02-01
Series:Journal of Nanobiotechnology
Subjects:
Transforming growth factor-β
Immune checkpoint inhibitors
Drug resistance
Polymeric nanoparticles
Tumor microenvironment
Online Access:https://doi.org/10.1186/s12951-025-03129-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12951-025-03129-z

Similar Items